BCMA is not only a plasma cell or MM cell marker but is also coexpressed on normal B cell lymphocytes; therefore, BCMA CAR T-cell therapy could also result in B-cell aplasia, which leads to increased infection risks [38]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.